Speakers - Sachs Associates
Speakers - Sachs Associates
Speakers - Sachs Associates
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Supporting Organisations<br />
Citigate Dewe Rogerson<br />
www.citigatedr.co.uk<br />
Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and<br />
corporate communications across the UK, Europe, North America and Asia.<br />
Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector<br />
and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic<br />
science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting<br />
from the company’s overall strength and from the cross-fertilisation of ideas across sectors.<br />
The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies<br />
at all stages in development. As well as core skills in financial calendar work, transactions support, financial<br />
PR and media relations, the team has extensive experience in branding, design and new media consultancy.<br />
Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging<br />
businesses in the UK, France, Germany, the Netherlands, and Scandinavia.<br />
Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public<br />
and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including;<br />
METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock Exchange - €30 million), Santhera<br />
Pharmaceuticals (SWX – CH88.5 million), ThromboGenics (Euronext Brussels - €35 million), Hutchison China<br />
MediTech (AIM - £40 million), Zentiva (LSE and PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE -<br />
£35 million), TopoTarget (CSE - €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million).<br />
Citigate Dewe Rogerson<br />
3 London Wall Buildings<br />
London Wall<br />
London EC2M 5SY<br />
Tel: +44 (0)-207-638-9571<br />
t back :: next u<br />
WELCOME PHARMA LICENSING GROUPS<br />
SPEAKERS<br />
PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />
ORGANISERS